IPCA LABORATORIES
|
The Current P/E Ratio of IPCA LABORATORIES is 36.28.
| Share Price | ₹1,973.2 | Nov 04,2026 |
| Market Cap | ₹50,058.8 Cr | |
| Earnings-TTM | ₹1,379.8 Cr | TTM-Consolidated Results |
| Price/Earnings | 36.28x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of IPCA LABORATORIES
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹50,058.8 Cr] as on Nov 04,2026
(/) Earnings [ ₹1,379.8 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 36.28x ]
Thus, for IPCA LABORATORIES , the investors are currently willing to pay 36.28 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of IPCA LABORATORIES !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of IPCA LABORATORIES over the last five years.
Historical PE (Price/Earnings) ratio chart of IPCA LABORATORIES
PE Ratio Performance Analysis for IPCA LABORATORIES
- IPCA LABORATORIES 's p/e ratio for fiscal years ending Mar2026 to Mar2022 averaged 43.75x.
- IPCA LABORATORIES 's operated at median p/e ratio of 43.62x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, IPCA LABORATORIES 's p/e ratio peaked in Mar2024 at 57.39x.
- IPCA LABORATORIES 's p/e ratio hit its five-year low in Mar2022 of 30.45x.
How does IPCA LABORATORIES 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| IPCA LABORATORIES | 1,379.76 | 36.28 | 50,058.8 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 11,037.20 | 38.61 | 426,122.0 |
| DIVIS LABORATORIES LTD | 2,925.00 | 91.09 | 266,424.0 |
| TORRENT PHARMACEUTICALS LTD | 2,099.00 | 85.71 | 179,914.0 |
| CIPLA LTD | 2,868.29 | 39.44 | 113,112.0 |
| DR REDDYS LABORATORIES LTD | 2,759.70 | 41.53 | 114,599.0 |
| MANKIND PHARMA LTD | 2,249.69 | 46.51 | 104,631.0 |
| LUPIN LTD | 5,221.47 | 17.65 | 92,144.5 |
| ZYDUS LIFESCIENCES LTD | 4,159.00 | 28.54 | 118,703.0 |
| AUROBINDO PHARMA LTD | 3,712.74 | 26.36 | 97,877.5 |
| LAURUS LABS LTD | 1,333.75 | 93.42 | 124,601.0 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs IPCA LABORATORIES 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 17.65x |
| Max industry PE | 93.42x |
| Median industry PE | 39.44x |
| Average industry PE | 49.56x |
You may also like the below Video Courses